Speakers will explore the impactful role of ADCs to treat HER2-positive metastatic breast cancer, lymphoma and other malignancies. Utilising case studies, discover the clinical significance of the advancements which are shaping the future of cancer health care.
Matthew Britland
Managing and Medical Director, Medwise Consulting
Matt is the immediate Past President of Medical Affairs Professionals of Australasia (MAPA, formerly APPA). He is also the Managing Director of MedWise Consulting, a specialist practice focused on medical affairs, medical communications, and patient affairs.
Matt is an experienced medical affairs leader and Medical Director with a demonstrated history of working in the pharmaceuticals industry and clinical roles for over 25 years.
Skilled in Pharmaceutical Medicine, Oncology and Haematology, Matt is a strong professional with a MMedSc focused in Pharmaceutical Medicine from UNSW Australia.
He is currently undertaking a Doctorate on the role of Medical Affairs in the Quality use of Medicine (QUM) and its impact on patient outcomes.
Bryce Davies
Head of APAC Strategy, Early Phase Oncology and Innovative Therapies, IQVIA
Bryce has 20 years of combined experience working with sponsors and at IQVIA. In his prior role, with a global biopharma, he was the Global Operations Lead for the Early Phase program and successfully transitioned nine compounds from early research (laboratory) to clinic and taken a further six molecules from escalation into expansion.
He has also been the Clinical Operations Lead on various regulatory filing (NDA) teams, delivering two FDA filings/approvals. In his current role, he has taken on leadership of Early Phase Oncology strategy and delivery within the JAPAC region. His responsibilities include developing and implementing strategic plans to ensure IQVIA remains at the forefront of oncology product development.
He actively engages with key stakeholders, including Early Phase Oncology Investigators and internal/external Subject Matter Experts.
Chair: Dr Jason Lickliter
Chief Medical Officer, Nucleus Network Pty Ltd
Dr. Jason Lickliter heads Nucleus Network’s Medical Department; this includes a multi-site team of Medical Officers. Jason has extensive experience across all aspects of early phase clinical trials from protocol design and implementation to the integration of Biomarker studies and advanced imaging into clinical research. With a Medical Oncology and Clinical Hematology background, his achievements include the establishment of a Phase 1 Cancer Trials Program at Monash Medical Centre.
Dr Peter Savas
Medical Oncologist, Peter MacCallum Cancer Centre
Medical Oncologist specializing in breast cancer. Extensive experience in Cancer Genomics, Data Analysis, Clinical Research, Clinical Trials, Precision Oncology and Immunotherapy.
Early career clinician scientist doing translational research to improve outcomes for breast cancer patients.
Key themes of my work are using cutting edge genomic and single cell technologies, artificial intelligence and machine learning.
